This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the most frequently ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...